	FORM PTO 1449 (modified)	Atty. Docket No. X-16603	Serial No
-	INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant BONJOUKLIAN, Rosanne et al.	
		Application Date US Nat'l Entry (if applicable)	Group Art Unit

xaminer	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No. 1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Pages or Relevant Figures Appear
	AA	US			
	AB	US			
	AC	US			
	AD	US			
	AE	US			
	AF	US			
	AG	US			
	AH	US			
	AI	US			
	AJ	US			
	AK	US			
	AL	US			
	AM	US			
	AN	US			
	AO	US			
	AP	US			

Examiner	Date Considered	
Signature		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <u>wow usplo gov</u> or MPEP 901 04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>2</sup> For Tapacese partent documents, the indication of the page of the Engage of t

FORM PTO 1449 (modified)	Atty. Docket No.	Serial No
	X-16603	
INFORMATION DISCLOSURE CITATION	First Applicant	
IN AN APPLICATION	BONJOUKLIAN, Rosanne et al.	
	Application Date	Group Art Unit
	US Nat'l Entry (if applicable)	

xaminer Initials*	Cite	Foreign Patent Document		Name of Patentee or	Proce Colomo Time	T <sup>6</sup>
Initials*	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code5 (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	BA	WO-97/25045-A	07-17-1997	ADAMS et al.		
	BB	WO-02/072576-A	09-19-2002	DOMBROSKI et al.		
	BC	WO-03/042211-A	05-22-2003	GASTER et al.		
	BD	WO-2004/014900-A1	02-19-2004	BONJOUKLIAN et al		
	BE					
	BF					
	BG					
	ВН					
	BI					
	BJ					
	BK					
	BL					
	BM					
	BN					
	ВО					
	BP					

Examiner	Date Considered	
Signature		

SEXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through estation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <u>wow usplo gov</u> or MPEP 901 04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>2</sup> For Tagascese patent documents, the indication of the page of the Engage of t

FORM PTO 1449 (modified)	Atty. Docket No. X-16603	Serial No
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	First Applicant BONJOUKLIAN, Rosanne et al.	
	Application Date US Nat'l Entry (if applicable)	Group Art Unit

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T6
Initials*	No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	
	CA	KAI, et al, Preparation of pyrazole derivatives as antiviral agents, Chemical Abstracts, XP002328394	
	СВ		
	CC		
	CD		
	CE		
	CF		
	CG		
	СН		
	CI		
	CJ		
	CK		
	CL		
	CM		
	CN		
	СО		

Examiner	Date Considered
Signature	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <u>wow usplo gov</u> or MPEP 901 04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>2</sup> For Tapacese partent documents, the indication of the page of the Engage of t

CERTIFICATION OF FACSI	MILE TRANSMISSION
nereby certify that this paper is being facsimile transmitted to t	he Patent and Trademark Office on the date shown below.
Type or print name of parec	n cianina cartification
Type or print name of perso	n signing certification

## <u>PATENT APPLICATION</u> IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant: BONJOUKLIAN, Rosanne et al.

For: Kinase Inhibitors

Docket No.: X-16603

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

/Robert D. Titus/

Robert D. Titus Attorney for Applicants Registration No. 40,206 Phone: 317-277-2739

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288